{"generic":"Aclidinium Bromide","drugs":["Aclidinium Bromide","Tudorza Pressair"],"mono":{"0":{"id":"930262-s-0","title":"Generic Names","mono":"Aclidinium Bromide"},"1":{"id":"930262-s-1","title":"Dosing and Indications","sub":[{"id":"930262-s-1-4","title":"Adult Dosing","mono":"<b>Bronchospasm - Chronic obstructive pulmonary disease:<\/b> INHALE 1 puff (400 mcg) ORALLY twice daily "},{"id":"930262-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy have not been established in pediatric patients "},{"id":"930262-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>geriatric:<\/b> no dose adjustment necessary<\/li><li><b>renal impairment:<\/b> no dose adjustment necessary<\/li><\/ul>"},{"id":"930262-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Bronchospasm - Chronic obstructive pulmonary disease<br\/>"}]},"3":{"id":"930262-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930262-s-3-9","title":"Contraindications","mono":"Specific contraindications have not been determined <br\/>"},{"id":"930262-s-3-10","title":"Precautions","mono":"<ul><li>Immunologic:<\/li><li>-- Immediate hypersensitivity reactions have been reported; immediate discontinuation recommended<\/li><li>-- Patients with a history of hypersensitivity reactions to atropine; monitor closely for similar hypersensitivity reactions<\/li><li>-- Use caution in patients with severe hypersensitivity to milk proteins<\/li><li>Ophthalmic:<\/li><li>-- Use caution in patients with narrow-angle glaucoma; worsening of condition may occur<\/li><li>Renal:<\/li><li>-- Use caution in patients with urinary retention; worsening of condition may occur<\/li><li>Respiratory<\/li><li>-- Paradoxical bronchospasm may occur; discontinue if occurs<\/li><li>Concomitant Use:<\/li><li>-- Avoid use with other anticholinergic-containing drugs<\/li><\/ul>"},{"id":"930262-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"930262-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"930262-s-4","title":"Drug Interactions","sub":{"1":{"id":"930262-s-4-14","title":"Major","mono":"<ul><li>Bupropion (theoretical)<\/li><li>Donepezil (theoretical)<\/li><\/ul>"}}},"5":{"id":"930262-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Neurologic:<\/b>Headache (6.6%)<\/li><li><b>Respiratory:<\/b>Cough (3%), Nasopharyngitis (5.5%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>First degree atrioventricular block (less than 1%), Heart failure (less than 1%)<\/li><li><b>Immunologic:<\/b>Hypersensitivity reaction<\/li><li><b>Respiratory:<\/b>Cardiorespiratory arrest (less than 1%)<\/li><\/ul>"},"6":{"id":"930262-s-6","title":"Drug Name Info","sub":{"0":{"id":"930262-s-6-17","title":"US Trade Names","mono":"Tudorza Pressair<br\/>"},"2":{"id":"930262-s-6-19","title":"Class","mono":"<ul><li>Antimuscarinic<\/li><li>Bronchodilator<\/li><\/ul>"},"3":{"id":"930262-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"930262-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"930262-s-7","title":"Mechanism Of Action","mono":"Aclidinium bromide is a long-acting antimuscarinic agent that inhibits the M(1) through M(5) receptors. Inhaled aclidinium bromide inhibits the M(3) receptor at the smooth muscle in the airways, leading to bronchodilation.<br\/>"},"8":{"id":"930262-s-8","title":"Pharmacokinetics","sub":[{"id":"930262-s-8-23","title":"Absorption","mono":"<ul><li>Tmax, Inhalation: within 10 minutes<\/li><li>Bioavailability, Inhalation: 6%<\/li><\/ul>"},{"id":"930262-s-8-24","title":"Distribution","mono":"<ul><li>Vd: 300 L<\/li><li>Vd, Renal impairment: 9972 to 13,346 L<\/li><\/ul>"},{"id":"930262-s-8-25","title":"Metabolism","mono":"majority by hydrolysis via esterases <br\/>"},{"id":"930262-s-8-26","title":"Excretion","mono":"<ul><li>Renal: 0.09% (inhalation); 54% to 65%, 1% unchanged (IV); 0.014% to 0.111% (renal impairment)<\/li><li>Fecal: 20% to 33%<\/li><li>Renal Clearance: 2.2 to 13.7 mL\/min (renal impairment)<\/li><li>Total body clearance: 170 L\/hr; 1745 to 3299 L\/hr (renal impairment)<\/li><\/ul>"},{"id":"930262-s-8-27","title":"Elimination Half Life","mono":"<ul><li>5 to 8 hours<\/li><li>Renal impairment, 2.07 to 4.18 hours<\/li><\/ul>"}]},"9":{"id":"930262-s-9","title":"Administration","mono":"<b>Inhalation<\/b><br\/><ul><li>press and release green button and then make sure control window has changed from red to green before inhalation<\/li><li>breathe out completely before forming a tight seal with lips around mouthpiece and breathe in; there will be a clicking sound; control window should turn red after inhalation<\/li><li>discard after the dose indicator displays a 0, the device locks out, or 45 days after removing the inhaler from the sealed pouch<\/li><\/ul>"},"10":{"id":"930262-s-10","title":"Monitoring","mono":"<ul><li>improvement in signs\/symptoms of bronchospasm associated with COPD is indicative of efficacy<\/li><li>hypersensitivity reactions; in patients with prior hypersensitivity to atropine<\/li><\/ul>"},"11":{"id":"930262-s-11","title":"How Supplied","mono":"<b>Tudorza Pressair<\/b><br\/>Inhalation Aerosol Powder: 400 MCG\/Actuation<br\/>"},"13":{"id":"930262-s-13","title":"Clinical Teaching","mono":"<ul><li>Drug may cause headache, cough, or common cold-like symptoms.<\/li><li>Instruct patient to report signs\/symptoms of allergic reaction including rash, hives, or swelling of the mouth, face, lips, or tongue.<\/li><li>Tell patient to report new or worsening urinary retention including difficult, frequent, or painful urination.<\/li><li>Advise patient to immediately report signs\/symptoms of glaucoma including new or worsening ocular pressure.<\/li><li>Instruct patient immediately report sudden shortness of breath following drug use.<\/li><li>Tell patient to immediately report exacerbation of breathing problems, increased use of a rescue inhaler, or if the rescue inhaler does not work as well at relieving symptoms.<\/li><li>Instruct patient to take drug twice daily approximately 12 hours apart.<\/li><li>Patient should avoid use of concomitant anticholinergics and\/or atropine.<\/li><li>Instruct patient to skip a missed dose and resume treatment with the next scheduled dose. Do not take a double dose.<\/li><\/ul>"}}}